Skip to content

Deep brain stimulation of the medial forebrain bundle for treatment-resistant depression

Deep brain stimulation of the medial forebrain bundle for treatment-resistant depression

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON20193
Enrollment
48
Registered
2019-12-03
Start date
2020-09-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment-resistant depression

Interventions

Deep brain stimulation (DBS) of the superolateral branch of the medial forebrain bundel (slMFB)

Sponsors

Board of directors, Amsterdam UMC (location AMC)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) A primary diagnosis of major depressive disorder (single episode or recurrent; 296.2 or 296.3) according to the DSM-5 criteria; 2) Treatment-resistance, which is defined in detail in Chapter 6.3; 3) HAM-D total = 18; 4) Illness duration > 2 years; 5) Disabling severity with substantial functional impairment; 6) Age: 20-70 years old; 7) Dutch or English speaking and able to answer the study questions; 8) Motivated and capable to attend the study visits; 9) Able to fully understand the consequences of the procedure; 10) Mentally capable to make his or her own choice without coercion; 11) Written informed consent

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1) Bipolar disorder; 2) Schizophrenia / history of psychosis unrelated to MDD; 3) Alcohol or substance abuse (including benzodiazepines) during the last 6 months; 4) Primary and severe personality disorder diagnosed independently from TRD; 5) Explicit suicidal plans requiring hospitalization in a closed ward; 6) Unstable physical condition or general contraindications to have surgery; 7) Depression as a result of acute brain damage (e.g. stroke / hemorrhage); 8) Parkinson’s disease, Tourette syndrome, dementia, epilepsy, tic disorder; 9) Pregnancy

Design outcomes

Primary

MeasureTime frame
Difference in scores between active and sham DBS on the Hamilton Depression Rating Scale, 17 items (HAM-D-17, range 0-52 with higher scores indicating more symptoms);

Secondary

MeasureTime frame
Secondary outcomes include percentage of responders after the open label phase (defined as a =50% reduction of the baseline HAM-D-17 score), (serious) adverse events, qualtiy of life, (neuro)psychological outcomes and neuro-imaging.

Contacts

Public ContactIsidoor Bergfeld

Academisch Medisch Centrum, Amsterdam

dbs-depressie@amsterdamumc.nl+31208913600

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)